Clinical Trials Browser

Terminated × NIH × Decitabine × Clear all

NCT05918055 2025-12-02

Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes

Phase 1/2 Terminated

3 enrolled 9 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03233724 2023-05-31

Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas

Phase 1/2 Terminated

9 enrolled 14 charts

GastrointestinalOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Lung Neoplasms

NCT00701298 2014-02-24

Decitabine With or Without Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Solid Tumors

Phase 1 Terminated

Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

NCT00049582 2013-09-30

Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia

Phase 1 Terminated

MyeloidOther hematologic neoplasm

Congenital Abnormalities, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

NCT00748527 2013-07-10

Carboplatin With or Without Decitabine in Treating Patients With Progressive, Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Phase 2 Terminated

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00042796 2013-01-23

Decitabine in Treating Children With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Phase 1 Terminated

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00089089 2013-01-07

Decitabine in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas

Phase 1 Terminated

Other hematologic neoplasm

Hematologic Neoplasms